Pan-RAS Inhibitor Daraxonrasib Delivers Landmark Survival Gains in Pancreatic Cancer
Two landmark New England Journal of Medicine studies show the pan-RAS inhibitor daraxonrasib nearly doubles survival in previously treated metastatic ...
Two landmark New England Journal of Medicine studies show the pan-RAS inhibitor daraxonrasib nearly doubles survival in previously treated metastatic ...
A large triple-blind French trial found that transcranial random noise stimulation was safe but no better than sham at easing ...
The PVI-SHAM-AF trial found that catheter ablation reduced atrial fibrillation recurrence and burden but did not significantly improve symptoms beyond ...
A double-blind clinical trial found that metabolites from folate-dependent one-carbon metabolism and the transsulfuration pathway, analyzed with machine learning, predicted ...
First clinical data from the Phase 1b/2 BNT324-01 trial show that the investigational combination of pumitamig and elfetabart drozuntecan achieved ...
Five-year results from the KEYNOTE-826 trial confirm that adding pembrolizumab to first-line chemotherapy delivers durable survival benefit for patients with ...
A 90-day randomized trial in Brazil found that the oral peptide Pep19 significantly improved abdominal fat distribution, HbA1c, and insulin ...
A raindrop-inspired mathematical framework shows that a PLA coating makes iron corrode three times faster yet four thousand times more ...
The phase 1 GlutaPanc trial shows that l-glutamine can be safely combined with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ...
The FDA has cleared a CU Anschutz clinical trial testing dual-target CAR T-cell therapy against advanced colorectal cancer and pediatric ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine